CytomX Therapeutics reports Q2 EPS (2c), consensus (20c)

Reports Q2 revenue $24.72M, consensus $13.88M. “In recent months, we have continued to advance our innovative Probody(R) Therapeutic pipeline, while making significant progress with our partners across a wide range of programs and therapeutic modalities,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX Therapeutics. “With a recent strategic financing completed with long-term CytomX shareholder, BVF Partners, we have strengthened our financial position and extended our cash runway into the second half of 2025.”